מנכ"ל טבע: "העתיד נראה מבטיח במיוחד; מסתכלים גם על רכישות גדולות יותר"

הערכה

Teva's CEO is signaling a strategic shift: the company now targets $6-7 billion in innovative drug revenue by 2030 and is open to larger acquisitions. The stock trades at a roughly 15% discount to larger biopharma peers despite strong industry growth. The gap between operational momentum and market valuation is the story to watch. If Teva delivers on its pipeline promises, that discount could close quickly.